Seattle Genetics exercises option to co-develop tisotumab vedotin for solid tumours

Danish biotechnology company Genmab and US-based Seattle Genetics are set to co-develop tisotumab vedotin for the treatment of patients with solid tumours.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news